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Summary Urinary mucins which express determinants for the anti-breast carcinoma monoclonal antibody,
NCRC-11 (IgM), closely resemble the mammary mucins found in milk fat globules and carcinomas. An IgG3
monoclonal antibody, C595, was prepared against urinary mucins isolated on a NCRC- II antibody affinity
column, and this 'second generation' antibody was shown to have a very similar pattern of reactivity to the
original NCRC-11 antibody. By immunohistology, the profile of reactivity of both antibodies with tumour and
normal tissue specimens was virtually identical. Both antibodies reacted with epithelial mucins isolated from
breast tumours or normal urine using an NCRC- II antibody affinity column, although the antibodies were
unreactive with other antigen preparations. Heterologous immunoradiometric assays ('sandwich' tests)
confirmed that NCRC- Il and C595 epitopes were co-expressed on the same molecule. C595 antibodies
inhibited the binding of radiolabelled NCRC- I antibodies to antigen, suggesting that the two epitopes were in
close topographical proximity. The protein core of the mammary mucins has recently been shown to consist
predominantly of a repeated 20 amino acid sequence (Gendler et al., 1988). Peptides with this complete
sequence and small fragments were synthesised, and the C595 antibody was found to recognise an epitope
within this repeat. The ability to identify and synthesise monoclonal antibody-defined determinants, as well as
those in the adjacent or overlapping sequences within the protein core of epithelial mucins, is viewed as a
strategy for facilitating the production of antibodies of new and novel specificity to complement the panels of
existing anti-breast cancer reagents.
High molecular weight glycoproteins, often described as
mucins or mucin-like glycoproteins, are frequently found
associated with breast carcinomas. These molecules have
been identified as the target antigens for many monoclonal
antibodies produced against breast carcinoma cells or human
milk fat globule membranes (Burchell et al., 1983; Hilkens et
al., 1984; Price et al., 1985; Sekine et al., 1985; Lan et al.,
1987). Such mucin antigens are clearly the products of nor-
mal epithelia and their secretions, as well as their malignant
cell counterparts. The relevance of epithelial mucins to
clinical studies in breast cancer is that they are detectable in
the serum of patients and levels are particularly elevated in
metastatic disease (reviewed in Kufe et al., 1988; Price, 1988).
Thus, there is intense interest in developing monoclonal
antibody based assays for these products in the circulation in
order that their clinical utility may be fully explored.
The monoclonal antibody, NCRC-l1, is one of those re-
agents produced against breast carcinoma cells which shows
characteristic reactivity with tumours and normal glandular
epithelia (Ellis et al., 1984). However, this antibody belongs
to the IgM immunoglobulin class which was considered to
limit its clinical potential as a tumour targeting antibody.
Therefore, the present investigation was initiated in an
attempt to produce 'second generation' IgG monoclonal anti-
bodies against mucin antigens bearing the NCRC-ll defined
epitope. Since normal urine has been found to be an abun-
dant source of epithelial mucin (Price et al., 1987a) (pre-
sumably originating by exfoliation from the urothelium
which reacts strongly with the NCRC-l1 antibody (Ellis et
al., 1984)), then urine was selected for antigen isolation
by immunoadsorbent chromatography using immobilised
NCRC-1 1 antibodies. One antibody, C595, raised against
normal urinary epithelial mucin, was selected for further
study and this has provided some insight into the nature of
the antibody-defined determinants of these mucins.
Materials and methods
Monoclonal antibodies
NCRC-l (IgM) was originally prepared using spleen cells
from a Balb/c mouse immunised against dissociated breast
carcinoma cells (Ellis et al., 1984). The antibody C595 (IgG3)
was prepared using spleen cells of a mouse immunised
against NCRC-I 1-defined epithelial antigen isolated from
normal urine. In the initial antibody screening tests, mass
culture supernatants and supernatants from cloned hybrid-
oma cells were selected for high reactivity against the
immunising antigen preparation using a radioisotopic anti-
globulin assay (Price et al., 1985). This initial selection was
followed by analyses of antibody reactivity with breast car-
cinoma tissue sections by immunocytochemistry.
NCRC-I I and C595 antibodies were purified by affinity
chromatography using Sepharose-lentil lectin and Sepharose-
protein A columns (Pharmacia, Uppsala, Sweden), respec-
tively.
The following murine antibodies were also used: C365 -
IgGl (anti-carcinoembryonic antigen, CEA); C161 - IgGI
(anti-normal cross-reacting antigen, NCA); C14 - 1gM (anti-
Y hapten, Ley) (Price et al., 1987b); the mouse myeloma
P3NS1 hybridoma culture supernatant.
Immunocytochemistry
Indirect immunoperoxidase tests were performed on cryostat
sections (5 jAm) fixed in acetone for 10 min on ice. Hybrid-
oma supernatant (50 1l per section) was added, and, after
incubation for 30 min and washing with phosphate buffered
saline (PBS, pH 7.3), peroxidase conjugated rabbit immuno-
globulins to mouse immunoglobulins (50 ilI per section, at a
dilution of 1/80 in PBS containing 1% normal human serum)
were added for 30 min followed by washing with PBS.
Finally, sections were incubated with 0.1%. diaminobenzi-
dine and 0.2% H202 (in Tris-buffered saline, pH 7.6) for
10min, washed in running tap water, counterstained with
haematoxylin, dehydrated, cleared in xylene and mounted.
Correspondence: M.R. Price.
Received 29 June 1989; and in revised form 9 October 1989.
'." Macmillan Press Ltd., 1990 Br. J. Cancer (1990), 61, 681-686682 M.R. PRICE et al.
Antigen preparations
NCRC-1 1 defined antigen preparations were isolated from
detergent (Nonidet P-40) solubilised subcellular membranes
from breast carcinomas and ovarian mucinous and serous
carcinomas by immunoadsorbent chromatography using
Sepharose-linked NCRC-l1 antibodies as previously describ-
ed (Price et al., 1985, 1986b). Samples of skim milk and
normal urine were also employed as the starting material for
NCRC-l1 defined antigen isolation although detergent was
not included in the initial sample solution or washing buffers
(Price et al., 1987a). In all cases, NCRC- 11 defined antigens,
after elution from the affinity column with 100 mM die-
thylamine (pH 11.5) and neutralisation with 1 M Tris-HCI
(pH 7.6) were dialysed overnight against PBS, centrifuged at
100,000g for 60min and stored at -20C.
Subcellular membrane fractions ('extranuclear' membranes,
ENM) were prepared from breast and colorectal carcinomas.
Normal membrane preparations were isolated from appar-
ently uninvolved tissues, adjacent to the tumour. ENM pre-
parations were obtained as the 100,000g pellets of 600g
supernatants of homogenates. Membranes were stored in
PBS at -20°C.
CEA was purified from colorectal tumour liver metastases
(Krupey et al., 1972), NCA was isolated by affinity chroma-
tography and Le' bearing glycoproteins were purified from
the sputum of a Y hapten positive secretor using affinity
chromatography (Price et al., 1986a).
Radioisotopic antiglobulin assay
Purified NCRC-11-defined antigen preparations (at concen-
trations predetermined to give optimal antibody binding with
low non-specific binding of irrelevant antibodies) or ENM
fractions (200,tg ml-' in PBS) were adsorbed to Terasaki
microtest plates (A/S Nunc, Roskilde, Denmark) by incuba-
tion at 37C for 18 h. The wells were washed 4 times
with a washing buffer of PBS + 0.1% bovine serum albumin
(BSA) + 0.1% rabbit serum (RbS) + 0.02% NaN3. During
the final wash cycle, the wells were incubated for 30 min with
washing buffer to complete the blocking of non-specific
adsorption binding sites.
Monoclonal antibodies or washing buffer were added at
10 LI per well. All monoclonal antibodies were added at
concentrations or dilutions predetermined in titration tests to
be at saturation. After incubation for 1 h at room tem-
perature, the wells were aspirated and washed 4 times with
washing buffer. '25I-labelled affinity purified F(ab')2 fragments
of rabbit anti-mouse Ig were added at 105 c.p.m.
10 o1' well-' (radio-iodination of this reagent was per-
formed using the chloramine T procedure of Jensenius and
Williams (1974) using 18 MBq 1251 per 25fig protein).
Incubation was continued for 1 h at room temperature. The
wells were then aspirated, washed 6 times, after which the
radioactivity in each well was determined.
'Sandwich' immunoradiometric assay (IRMA)
Purified antibodies (at 10 ytg ml-' in PBS + 0.02% NaN3)
were adsorbed on to the wells of Terasaki microtest plates.
After incubation at 5C for 18 h, the wells were aspirated and
washed 4 times with washing buffer. On the fourth wash
cycle, the plates were incubated with the washing buffer for
1 h in order to block any remaining non-specific binding
sites. Aliquots (10fl) of affinity purified NCRC-1 1 defined
antigen, diluted in washing buffer, or washing buffer alone,
were added to the wells. After incubation for I h at room
temperature, the wells were aspirated and washed 4 times.
'25I-NCRC-1 1 antibody (radiolabelled using 18 MBq 1251 per
25 sg protein according to Jensenius and Williams (1974) was
added at I05 c.p.m. 10 sl-' well-' and incubated for 1 h
at room temperature. The wells were then aspirated, and
washed 6 times, after which the radioactivity in each well was
determined.
Immunoblotting
NCRC-l1 defined antigen preparations were diluted 1:1 in
SDS PAGE reducing sample buffer and then applied to a
7.5% polyacrylamide gel, with a 4% stacking gel, using an
LKB Midget Gel Electrophoresis Apparatus. Electrophoresis
was performed at 300 V for 50 min using the discontinuous
buffer system of Laemmli (1970).
Electroblotting onto nitrocellulose membranes was per-
formed as described by Towbin et al. (1979) using the Biorad
Transblot Apparatus for 20 h at 50 V and 200 mA in 25 mM
Tris, 192 mM glycine buffer, pH 8.3, containing 20% meth-
anol. Immunostaining of antigen with NCRC-1 1 and C595
antibodies was performed as previously described (Price et
al., 1987a).
CsCIgradient centrifugation
Affinity purified epithelial antigen from urine was subjected
to CsCl density gradient centrifugation in a 6 x 16.5 swing-
out rotor (MSE Scientific Instruments, Crawley, UK) oper-
ated at 110,000g for 70 h at 10°C. The gradient prepared
with a starting density of 1.46 gml' and, after centrifuga-
tion, 1 ml fractions were collected from the base of each
tube. The density of each fraction was determined gravi-
metrically and, after dialysis against PBS, fractions were
tested for antigenic activity.
Peptide synthesis
Synthesis was carried out on a manual solid phase peptide
synthesiser (Biolynx 4175), using the continuous Fmoc/poly-
amide methodology and Ultrosyn A resin (Pharmacia LKB
Biotechnology) functionalised at a level of 0.09 mEq g-', was
employed. The following amino acid side chain protecting
groups were used: histidine, t-butoxycarbonyl (Boc); serine
and threonine, t-butyl; arginine, 4-methoxybenzenesulphonyl
(Mtr)
Simultaneous deprotection and cleavage of peptide from
the resin was performed using either 95% trifluoroacetic acid
(TFA) or 5% thioanisole in anhydrous TFA (for P(1-20)).
Peptides were purified by HPLC using a gradient elution
profile, the eluants being 0.1% aqueous TFA and 0.1% TFA
in 90% aqueous acetonitrile.
Results
Immunocytochemical staining oftissues
Table I summarises the results of a comparative analysis
of the reactivity of the antibodies C595 and NCRC-1 I with
a series of breast carcinomas and normal tissue specimens.
With tumours, NCRC- 1I staining was variable between
tumours and heterogeneous within individual tumours, as has
been previously reported (Ellis et al., 1984). The pattern of
reactivity of the C595 antibody was essentially identical
although the intensity of staining appeared slightly weaker
than with NCRC-11. C595 showed no faint non-specific
staining of stromal elements, which was occasionally ob-
served with NCRC-l1 antibody.
C595 staining of normal tissues was virtually indistinguish-
able from that of NCRC-11. The antigen(s) recognised had a
highly specific distribution in normal tissues and was con-
fined to the luminal surface of specific epithelia, including the
urothelia (Table I). There was little variability in the level
of staining by either antibody when tested against sections
from different normal tissue blocks from the same organ, or
from different tissue donors. The profile of staining of nor-
mal tissues by NCRC- 1I antibody corresponded to that
originally described in detail by Ellis et al. (1984).C595 - NEW ANTI-URINARY MUCIN ANTIBODY 683
Table I Immunocytochemical staining oftissues
Tissue staining with
System Tissue C595 NCRC-11
Tumours Breast carcinoma 7/8 6/8
Normal tissuesa
Alimentary system Stomach - -




Cerebral cortex - -
Lymphoreticular Spleen/Lymph nodes - -
system
Generative system Breast
Acini and Ducts + +
Testis




Distal tubules + +
Collecting tubules + +
Bladder + +
Respiratory system Lung + +
aThe reactivity of antibodies with normal tissues was assessed on
sections from several tissue blocks from at least two tissue donors
(obtained at post mortem), as well as freshly collected surgical
specimens.
Reactivity ofmonoclonal antibodies with subcellular
membranes
The reactivity of C595 and NCRC-11 antibodies with subcel-
lular membranes (ENM, 'extra-nuclear' membranes) from
normal and malignant breast tissue was examined using a
solid phase radioisotopic antiglobulin assay (Table II). Both
NCRC-1 1 and C595 antibodies showed greater levels of re-
activity with tumour ENM compared with ENM derived
from normal tissue specimens although overall, the C595
appeared to display a more enhanced descriminatory capacity
for tumours. It should be noted that the actual level of
reactivity of NCRC-l1 binding to normal ENM (three of
four samples) was only slightly elevated above the positivity
cut-off value of 1,000 c.p.m. (reactivity score ) 1) and that
NCRC-l1 antibody binding to normal tissue ENM was not
substantially higher than that of C595 (Table II). Three
control monoclonal antibodies were included in these tests:
antibodies against CEA, NCA and the Y-hapten. While the
anti-CEA antibody failed to show high binding to either
normal or tumour ENM from breast tissues, both anti-NCA
and anti-Ley antibodies were in fact discriminatory (this
being a consistent unpublished observation in these
laboratories).
Neither C595 nor NCRC-11 reacted with normal or
tumour colorectal ENM preparations (Table II), whereas the
control antibodies against CEA, NCA and the Y-hapten
reacted with these materials, with anti Y-hapten antibodies
showing the greatest preferential reactivity towards tumour
ENM samples. It is probable that the ENM-antibody bind-
ing assay is less sensitive than immunohistology since
evidence for NCRC-l antibody binding to colonic tumours
has been reported (Ellis et al., 1984). Thus, the positive
reactivity of antibodies with breast tumour ENM and
negative responses with colorectal tumour ENM are likely to
reflect quantitative differences in antigen content in the tissue
rather than qualitative differences in antigen expression.
Reactivity ofmonoclonal antibodies with purified antigens
Table III illustrates the reactivity of C595 and NCRC-1
antibodies with various purified antigen preparations. Both
antibodies reacted positively with epithelial mucin prepara-
tions isolated from detergent-solubilised breast carcinoma
membranes or from normal urine by affinity chromatography
using Sepharose-linked NCRC-1I antibodies. In cross tests,
these antibodies failed to react with purified CEA, NCA or
Ley-bearing glycoproteins. Conversely, antibodies against
CEA, NCA or the Y-hapten did not bind to either epithelial
mucin preparation although positive reactions were noted
with their appropriate target antigen.
Epithelial mucin antigen, isolated from normal urine by its
binding to and elution from immobilised NCRC-I 1 anti-
bodies, was loaded as sample on SDS PAGE gels. After
electrophoresis, antigen was transferred to nitrocellulose
membranes by Western blotting. Immunostaining with C595
and NCRC- 11 antibodies revealed identical banding patterns,
with staining confined to a major band in excess of 400 kDa
towards the top of the gel (Figure 1). No further bands were
noted when whole urine was subjected to equivalent analysis.
The urinary mucin antigen (Figure 1) was subjected to
CsCl density gradient centrifugation and fractions were
evaluated for C595 and NCRC-l antibody binding. With
both antibodies, the main peak of antibody binding activity
was located in a fraction of density around 1.42 gml' as
appropriate for mucinous glycoproteins (Figure 2).
Co-expression ofC595 and NCRC-JI definedepitopes on
epithelial mucins
Immunoradiometric assays ('sandwich' tests) were performed
to evaluate the expression of the C595 and NCRC-11 defined
epitopes on individual epithelial mucin molecules. A series of
epithelial mucin antigens were included in this analysis. These
were isolated from breast carcinomas (two preparations),
ovarian mucinous and serous carcinomas, normal urine (two
TableII Reactivity ofmonoclonal antibodieswithsubcellularmembranesfromnormaland tumourbreast
and colorectal tissues
Reactivity" with
Membranes Normal ENM Tumour ENM
(ENM) Mean % Mean %
preparedfrom Antibody nb ±s.d. R + ve n ±s.d. R + ve
Breast tissue P3NS1 4 0±0 - 0 15 0±0 - 0
C595 4 0±0 - 0 15 1.6±1.1 0+3 87
NCRC-11 4 0.8±0.5 0+1 75 15 1.6±1.3 0+3 73
Anti-CEA 4 0±0 - 0 15 0.6±0.9 0 >3 40
Anti-NCA 4 0.3±0.5 0+1 25 15 2.1±1.4 0+4 87
Anti-Ley 4 0±0 - 0 15 1.5± 1.4 0+3 60
Colorectal P3NS1 6 0±0 - 0 6 0±0 - 0
tissue C595 6 0±0 - 0 6 0±0 - 0
NCRC-11 6 0±0 - 0 6 0±0 - 0
Anti-CEA 6 2.0±0.6 1+3 100 6 3.0±0.6 2+4 100
Anti-NCA 6 2.7±1.0 1+4 100 6 3.2±0.4 3+4 100
Anti-Ley 6 0.3±0.8 0+2 17 6 1.7± 1.0 0+3 83
aReactivity scores: 0, <1,000 c.p.m.; 1, 1,000-1,999 c.p.m.; 2, 2,000-3,999 c.p.m.; 3, 4,000-
7,999 c.p.m.; 4, 8,000-11,999 c.p.m.; 5, > 12,000c.p.m. bn, number of samples tested; s.d., standard
deviation; R, range.684 M.R. PRICE et al.
Table III Reactivity ofmonoclonal antibodies with purified antigens
Reactivity ofmonoclonal antibodies
Antigen P3NS1 C595 NCRC-11 Anti-CEA Anti-NCA Anti-Ley
Epithelial mucin from 0 3 3 0 0
breast ca. (no. 1)
Epithelial mucin from 0 3 2 0 0 0
urine (no. 2)
Carcinoembryonic antigen 0 0 0 4 4 1
(CEA)
Normal cross-reacting 0 0 0 0 3 0
antigen (NCA)
Le' bearing glycoproteins 0 0 0 0 0 3
from sputum








Figure 1 SDS PAGE-Western blot analysis of NCRC- I defined
antigen isolated from normal urine. The nitrocellulose sheet in
lane A was probed with the C595 antibody, and in lane B
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Figure 2 CsCl density gradient centrifugation of NCRC-11
defined antigen isolated from normal urine. Fractions were tested
for reactivity with the C595 antibody in the upper panel and with
the NCRC-I I antibody in the lower panel. Density (g ml- ) -0-;
C595 antibody binding (c.p.m.) -0- (upper panel; NCRC-1I1
antibody binding (c.p.m.) -0- (lower panel).
preparations) and human skim milk. In each case the mucin
antigens were purified by their binding to and elution from
a Sepharose-NCRC-11 antibody immunoadsorbent column.
Each preparation consisted of high molecular weight glyco-
proteins (>400 kDa) as assessed by SDS PAGE, Western
blotting and immunostaining with NCRC-l1 antibody (Price
et al., 1985, 1986b, 1987a).
As shown in Table IV, these individual antigen prepara-
tions were examined for their capacity to 'bridge' C595
antibody adsorbed to the wells of microtest plates (i.e. the
'capture antibody'), and '25I-labelled C595 antibody (the
'tracer antibody'). This formation of complexes was achieved
with each antigen, indicating that the C595-defined epitope is
a repeated structure of these molecules which may be isolated
from both normal body fluids and malignant tissues (Table
IV). These experiments were extended and each antigen
preparation was examined for its capacity to bridge all possi-
ble combinations of 'capture' and 'tracer' antibodies using
C595 and NCRC-l 1 in both homologous and heterologous
IRMA formats. As with C595 antibody tests (first data col-
umn in Table IV), all antigens successfully bridged NCRC-l 1
antibodies when used as both the 'capture' and 'tracer'
antibodies (second column in Table IV). Thus, the NCRC-l 1
defined epitope is also a repeated determinant of the
antigens. In heterologous combinations of C595 and
NCRC-l 1 antibodies, again all antigens were capable of
completing the 'sandwich' complex so that C595 and
NCRC-l 1 epitopes are co-expressed upon individual mole-
cules in these epithelial mucin preparations (third and fourth
columns in Table IV).
Unlabelled C595 and NCRC-l 1 antibodies (in hybridoma
tissue culture supernatants or as purified antibodies) were
examined for their capacity to compete with '25I-labelled
NCRC-l 1 antibodies in their binding to urinary epithelial
mucin antigen adsorbed to the wells of the microtest plates.
As shown in Table V, C595 antibody displayed an inhibitory
capacity which was virtually identical to that of unlabelled
NCRC-l 1 antibodies. This would indicate that the epitopes
for the two antibodies are either identical, or that they are in
Table IV Homologous and heterologous IRMAs using C595 and
NCRC- II antibodies
Binding oftracer antibody to antigena at dilutions of
1/1- 1/10 - 1/100 - I/oo using the capture and tracer
Epithelial (*) antibodies
mucin CS95 & NCRC-11 & CS95 & NCRC-11 &
isolatedfrom CS95* NCRC-11* NCRC-11* C595*
Breast ca. 3-1_0_0b 5-4-2-0 5-5-2-0 3-2-1-0
(no. 1)
Breast ca. 3-2-0 5-4-3-0 5-3-0 3-2-0
(no. 2)
Ov. muc. ca. 3-2-0-0 5-4-3-0 5-4-2-0 3-3-2-0
Ov. ser. ca. 4-1-1-0 4-3-3-0 4-3-3-0 3-2-0-0
Urine (no. 1) 5-2-0-0 5-4-1-0 5-4-0-0 5-3-0-0
Urine (no. 2) 5-4-2-0 5-5-4-0 5-5-3-0 5-5-2-0
Skimmed 2-1-0-0 5-3-0-0 5-2-0-0 3-2-0-0
milk
aInitialconcentration ofeachantigenpreparationwasestimated to be
approximately 00 lAg ml-'. bReactivity scores as in Table II.
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Table V Inhibition ofbinding of '251-labelled NCRC-11 antibody to
epithelial mucin from urine
Percentage inhibition ofbinding of)25I- Material labelled NCRC-I1 antibody to epithelial
testedfor Concentration mucin using
inhibitory (Lgml-') or-
activity dilution tested P3NSI NCRC-11 C595 Anti-CEA
Hybridoma 1/1 -4±5 85±1 67±4
culture fluid 1/10 -9±2 63±3 51±3
1/100 -2±8 10±5 10±8
1/co 0±4 0±2 0±1
Purified 10 94±3 72±1 -2 ±7
antibody 3 62±3 43±6 -13±3
1 36± 10 30±6 -8 ±3
0 0±5 0±9 0 ± 2
Table VII Inhibition of binding of epithelial mucin to antibody by
pre-incubation ofantibody with synthetic peptides
Percentage inhibition (mean±s.d.) ofbin-
Con. of ding ofepithelial mucin bypre-incubation inhibiting of 'capture' antibody with peptide
'Capture' peptide
Expt antibody (sgml-') PBS P(12-20) P(7-20) P(1-20)
I C595 500 0±4 -40±12 97±2
NCRC-1 1 500 0± 5 -22± 12 -12±7
2 C595 500 0±4 -11±3 96±2
NCRC-1 1 500 0±11 -32±6 -12±7
3 C595 50 0±6 12±2 8±8 83±5
15 0±5 11±5 3±6 78±3
5 0±2 4±11 5±5 60±3
Discussion
sufficiently close topographical proximity for there to be
effective competitive inhibition of antibody binding. As
negative controls, neither the mouse myeloma P3NS1 culture
supernatant or an anti-CEA monoclonal antibody was found
to inhibit '251-labelled NCRC-11 antibody binding to
immobilised antigen (Table V).
Reactivity ofC595 and NCRC-JJ monoclonal antibodies with
synthetic peptides
Three synthetic peptides, of 9, 14 and 20 amino acids, were
prepared with sequences based upon those of the protein core
of mammary epithelial mucins, as reported by Gendler et al.
(1988). The sequences of these peptides, P(12-20), P(7-20)
and P(1-20), are illustrated in Table VI. When these peptides
were adsorbed to the wells of microtest plates and tested as
target 'antigens' for C595 or NCRC-1 1 antibody binding, no
positive signals were obtained, and it was considered prob-
able that the peptides were lost from the wells during the
extensive plate washing. Therefore, each peptide was tested
for its capacity to inhibit the binding of purified urinary
mucin to antibody adsorbed to the wells of a microtest plate
using the 'sandwich' assay format. Thus, antibody coated
plates were pre-incubated with peptides at various concentra-
tions before addition of antigen, then washing and addition
of a radiolabelled 'tracer' antibody. Using the NCRC-1
antibody as 'capture' and 'tracer' antibody, none of the
peptides at concentrations of 500tLg ml-' were able to inhibit
antigen binding and 'bridging' between the antibodies
(experiments 1 and 2, Table VII). However, when C595
antibody was the 'capture' antibody, the peptide P(1-20),
but not smaller peptides, produced 97 and 96% inhibition of
antigen binding at 500 pg ml-' (experiments 1 and 2), and
even at 5 tg ml1', P(1-20) produced 60% inhibition of
antigen binding (experiment 3, Table VII). These findings
suggest that the epitope for the antibody, C595, resides in the
protein core of epithelial mucins.
Finally, it should be noted that an IgM antibody such as
NCRC-1 1, on binding to a macromolecular antigen with
repeating epitopes, may achieve a multiple binding bonus
which renders competition by a peptide much less effective
than with an IgG antibody like C595. Thus, it cannot be
concluded from the experiments in Table VII that the
NCRC-1 antibody defines a non-protein epitope.
Production of a 'second generation' monoclonal antibody
against a urinary epithelial mucin antigen which has been
immuno-affinity purified using an antibody of the 'first
generation', has yielded an antibody, C595, of virtually iden-
tical specificity to its 'parent' but of the immunoglobulin IgG
class rather than being an IgM antibody. In fact, the data in
Tables I to V and Figures I and 2 all serve to emphasise the
similarities between the two antibodies, C595 and NCRC-l 1.
The preliminary survey of antibody reactivity with normal
tissues and breast tumours, by immunohistology (Table I) or
in subcellular membrane binding assays (Table II), revealed
little difference between C595 and NCRC- 11 antibodies. Fur-
thermore, in immunoblotting experiments, both antibodies
bound to high molecular weight antigens (Figure 1) which
were of high bouyant density (Figure 2). The reactivity of the
two antibodies in various immunoassays also exemplified
their siimilarities (Tables III to V).
In Table VII, the binding of urinary mucin to C595
antibody was clearly inhibited by incubation of antibody
with the synthetic peptide, P(1-20), which represents the
complete peptide motif which is repeated in epithelial mucins
(Gendler et al., 1988). This would indicate that the epitope
for C595 is expressed within the protein core of the mucin.
Since C595 failed react with all but the largest peptide, then
it might be anticipated that its epitope will be found within
the first half of the peptide P(1-20), within the sequence
P D T R P A P G S T (Table VI).
It appeared not to be possible to modify antigen binding
to the antibody NCRC-I 1 by equivalent incubation with the
synthetic peptides (Table VII). This might be taken to sug-
gest that NCRC-1 1 antibody reacts with a non-protein deter-
minant perhaps expressed within the carbohydrate domains
of the mucin, rather than in the protein core. Alternatively,
synthetic peptides may be less potent inhibitors of multi-
valent IgM antibodies (e.g. NCRC-1 1) as compared with IgG
antibodies such as C595. Most recent results have demon-
strated that both C595 and NCRC-11 antibodies bind to
peptides which have been synthesised on a solid phase
('tethered' peptides), so that the tests described in Table VII
may have been inappropriately designed to reveal the interac-
tion ofpeptide determinants with NCRC-1 1 antibodies of the
IgM class. Studies are in progress to localise the epitopes for
C595 and NCRC- I antibodies more precisely within the
protein core sequence.
Since the protein core of epithelial mucins consists of
Table VI Epithelial mucin core - Antibody reactivity with synthetic peptides
Amino acid number Reaction ofantibody
Peptide 1 5 10 15 20 NCRC-11 C595
P (12-20) PPAHGVTSA - -
P (7-20) PGSTAPPAHGVTSA - -
P(1-20) PDTRPAPGSTAPPAHGVTSA +
* * * * *
*Potential glycosylation sites.686 M.R. PRICE et al.
tandem repeats of 20 amino acid peptide, this provides an
adequate model incorporating the multiple repeats of the
C595 and NCRC-11 defined epitopes which are required for
the isolated antigen to 'bridge' homologous and heterologous
combinations of these two antibodies in IRMAs (Table IV).
Comparably, the close proximity of the peptide regions
which are likely to express the epitopes for C595 and NCRC-
I I antibodies would explain why C595 antibody was almost
as effective as NCRC- 11 antibody at inhibiting radiolabelled
NCRC-l1 antibody binding to antigen (Table V).
Evidence is now accumulating that a number of antibodies
produced in different laboratories react with the protein core
of epithelial mucins rather than with the carbohydrate side
chains (e.g. antibodies HMFG-1, HMFG-2, SM-3; Burchell
et al., 1987). Preferential reactivity of anti-core antibodies for
tumours may be achieved if the peptide core is more accessi-
ble in malignancy-derived mucins. This is feasible since in
tumours, aberrant or incomplete glycosylation as well as the
action of tumour-associated glycosidases and glycosyltrans-
ferases, may well generate core epitopes which are more
cryptically expressed (i.e. less accessible) in normal tissue
mucins. Staining of tumour tissue sections by NCRC- I1 and
C595 antibodies certainly displays wide heterogeneity both
within and between specimens, and this may reflect
differences in the accessibility or exposure of mucin protein
core epitiopes in malignant tissues. Also, staining when
observed in normal tissues (and only then, confined to the
luminal surface of specialised epithelia) does not appear to
attain the same intensity as can be found throughout some,
but not necessarily all, tumour tissue sections - thus, the
total antigen content or load in breast carcinoma tissue can
be considerably greater than in the corresponding normal
tissue. If irregular staining of tumour cells is due to incom-
plete or defective synthesis or carbohydrate chains, then it
follows that there may also be epitopes generated in tumour
mucin oligosaccharides which are preferentially associated
with tumours. The fact remains, however, that with the
insight gained upon the nature of the protein core and its
antibody defined epitopes, it becomes a feasible objective to
design strategies for the production of new antibodies with
increased tumour reactivity using more rational approaches
than was formerly possible.
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